Tofacitinib

BreastfeedingGeriatricPediatric

FDA APPROVAL DATE: 11/06/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Azathioprine, Biologic disease-modifying antirheumatics, Cyclosporine, CYP3A4 inhibitors, Fluconazole, Ketoconazole, Live vaccines, Potent immunosuppressives, Rifampin, Strong CYP inducers, Strong CYP2C19 inhibitors, Tacrolimus

PREGNANCY CATEGORY: C

SERIOUS INFECTIONS AND MALIGNANCY

See full prescribing information for complete boxed warning.

Our database has 63 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
RENAL
RESPIRATORY
OTHER


Page last updated 04/09/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric